NCT07168785Not yet recruitingEarly phase 1
[18F]-AraG PET Imaging in LA HNSCC
[18F]-AraG PET Imaging for Enhanced Risk Stratification and Chemoradiotherapy Response Assessment in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
This study will use \[18F\]-AraG PET/CT scans to monitor patients who have been diagnosed with locally advanced Head and Neck Squamous Cell carcinoma (LA-HNSCC), and are planning to undergo standard of care chemoradiotherapy for treatment.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- First submitted
- 27 Aug 2025
- Start date
- Sept 2026
- Primary completion date
- Jun 2027
- Lead sponsor
- Indiana University
- Diseases
- Head and neck cancer
- NCT number
- NCT07168785
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 5
- From Sept 2026 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosis of immunodeficiency or receiving systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to the PET/CT scan.
- Patients that will receive definitive induction chemotherapy or surgery.
- Patients who are unable to complete the radiation therapy.
Other
- Pregnant or breastfeeding.
Who the study is looking for
- Patients ≥18 years of age.
- Ability to provide written informed consent and HIPAA authorization.
- LA-HNSCC in the larynx, hypopharynx, or human papillomavirus (HPV) negative oropharynx and is planning to receive definitive CRT as the SOC treatment, which includes a total of 70 Gy of radiation dose in 35 fractions, delivered over 5 days a week for 7 weeks, as well as planned weekly cycles of cisplatin (CDDP).
- Tumor stage III and IV (AJCC 8th edition).
- Unresectable cases.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Willing and able to maintain the imaging protocol.
- Patients planning to receive pre-CRT and post-CRT FDG PET/CT scans as part of the standard clinical practice.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Indiana University Coordinator of this site? Confirm its status | Indianapolis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.